<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Value Research Online</title>
        <atom:link href="/stories/stock/40940/ajanta-pharma-ltd/rss/" rel="self" type="application/rss+xml" />
        <link>https://www.valueresearchonline.com/</link>
        <description>RSS Feeds | Value Research</description>
        <language>en</language>
        <copyright>Copyright 2026 Value Research India Private Limited.</copyright>
        <image>
            <title>Value Research</title>
            <url>https://www.valueresearchonline.com/assets/images/valueresearchonline-desktop.png</url>
            <link>https://www.valueresearchonline.com/</link>
        </image>

        <item>
			<title>50 long-term wealth builders</title>
			<link>https://www.valueresearchonline.com/stories/45849/50-long-term-wealth-builders/</link>
			<pubDate>Mon, 09 Jul 2018 14:33:15 +0530</pubDate>
			<category>Data for Thought</category>
			<description>&lt;img src=&quot;https://www.valueresearchonline.com/content-assets/images/45849_50__w320__h240__.jpg&quot; alt=&quot;50 long-term wealth builders&quot; border=&quot;0&quot; width=&quot;320&quot; height=&quot;240&quot; style=&quot;float: left; margin-right: 5px;&quot;&gt;Here&#039;s a list of stocks that fell big but bounced back much bigger</description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/45849/50-long-term-wealth-builders/</guid>
		</item>
		<item>
			<title>All it takes is three years</title>
			<link>https://www.valueresearchonline.com/stories/35167/all-it-takes-is-three-years/</link>
			<pubDate>Tue, 13 Feb 2018 11:51:59 +0530</pubDate>
			<category>Stockwire</category>
			<description>&lt;img src=&quot;https://www.valueresearchonline.com/content-assets/images/35167_20180213-ad__w320__h240__.png&quot; alt=&quot;All it takes is three years&quot; border=&quot;0&quot; width=&quot;320&quot; height=&quot;240&quot; style=&quot;float: left; margin-right: 5px;&quot;&gt;These companies have a history of doubling their profits every three years</description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/35167/all-it-takes-is-three-years/</guid>
		</item>
		<item>
			<title>Is your company's RoCE rising every year?</title>
			<link>https://www.valueresearchonline.com/stories/30865/is-your-company-s-roce-rising-every-year/</link>
			<pubDate>Mon, 18 Apr 2016 15:50:38 +0530</pubDate>
			<category>Stockwire</category>
			<description>We have a list of companies that have witnessed a consistent rise in RoCE in the past five years></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/30865/is-your-company-s-roce-rising-every-year/</guid>
		</item>
		<item>
			<title>New Drug Gainer</title>
			<link>https://www.valueresearchonline.com/stories/27843/new-drug-gainer/</link>
			<pubDate>Thu, 07 May 2015 12:14:13 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>Ajanta Pharma&#039;s approach of concentrating on branded formulations &amp; launching new drugs has worked out well for it></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/27843/new-drug-gainer/</guid>
		</item>
		<item>
			<title>First Launch Winner</title>
			<link>https://www.valueresearchonline.com/stories/26851/first-launch-winner/</link>
			<pubDate>Thu, 01 Jan 2015 09:02:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>From Pinkoo gripe water to branded formulations, Ajanta has come a long way. A specialist in cardio-vasculars, Ajanta&#039;s sales are well diversified between Africa and Asia></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/26851/first-launch-winner/</guid>
		</item>
		<item>
			<title>Selectively Generic</title>
			<link>https://www.valueresearchonline.com/stories/20766/selectively-generic/</link>
			<pubDate>Thu, 23 Aug 2012 14:49:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>Ajanta Pharma’s entry into the US &amp; EU markets is likely to be its key growth driver…></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/20766/selectively-generic/</guid>
		</item>
    </channel>
</rss>
